Coherus Biosciences Inc (NASDAQ: CHRS): Get Ready For The Next Few Months

In the last trading session, 1.5 million shares of the Coherus Biosciences Inc (NASDAQ:CHRS) were traded, and its beta was 0.55. Most recently the company’s share price was $2.18, and it changed around $0.11 or 5.31% from the last close, which brings the market valuation of the company to $247.43M. CHRS currently trades at a discount to its 52-week high of $8.33, offering almost -282.11% off that amount. The share price’s 52-week low was $1.43, which indicates that the current value has risen by an impressive 34.4% since then. We note from Coherus Biosciences Inc’s average daily trading volume that its 3-month average coming to 3.24 million.

Coherus Biosciences Inc stock received a consensus recommendation rating of Buy, based on a mean score of 1.29. If we narrow it down even further, the data shows that 0 out of 8 analysts rate the stock as a Sell; another 2 rate it as Overweight. Among the rest, 0 recommended CHRS as a Hold, whereas 6 deemed it a Buy, and 0 rated it as Underweight. Coherus Biosciences Inc is expected to report earnings per share of $Coherus BioSciences, Inc. for the current quarter.

Coherus Biosciences Inc (NASDAQ:CHRS) trade information

Instantly CHRS has showed a green trend with a performance of 5.31% at the end of last trading. The performance over the last five days has remained in the red territory. The company’s shares are currently down -34.53% year-to-date, but still down -0.91% over the last five days. On the other hand, Coherus Biosciences Inc (NASDAQ:CHRS) is -13.15% down in the 30-day period.

The consensus price target as assigned by Wall Street analysts is $9, which translates to bulls needing to increase their stock price by 75.78% from its current value. Analyst projections state that CHRS is forecast to be at a low of $7 and a high of $11.

Coherus Biosciences Inc (CHRS) estimates and forecasts

Coherus Biosciences Inc share prices are performing particularly well compared to other companies within the same industry. As is evident from the statistics, the company’s shares have fallen -38.59 percent over the past six months and at a 100.51% annual growth rate that is well above the industry average of 13.30%.

Looking at the company’s year-over-year earnings, the past five years showed a positive earnings growth rate of 4.73%.